Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 36; no. 15_suppl; p. 1005
Main Authors Jerusalem, Guy Heinrich Maria, Kovalenko, Elena, Yardley, Denise A., De Boer, Richard H., Hurvitz, Sara A., Ejlertsen, Bent, Blau, Sibel, Ozguroglu, Mustafa, Landherr, Laszlo, Ewertz, Marianne, Taran, Tanya, Fan, Jenna, Noel-Baron, Florence, Louveau, Anne-Laure, Burris, Howard A.
Format Journal Article
LanguageEnglish
Published 20.05.2018
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/JCO.2018.36.15_suppl.1005